Compare AIMD & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIMD | QNRX |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 9.2M |
| IPO Year | 2008 | 2023 |
| Metric | AIMD | QNRX |
|---|---|---|
| Price | $1.44 | $6.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.5K | ★ 899.0K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,157.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 498.95 | N/A |
| 52 Week Low | $1.26 | $3.25 |
| 52 Week High | $4.44 | $41.80 |
| Indicator | AIMD | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 67.90 |
| Support Level | $1.42 | $4.09 |
| Resistance Level | $1.65 | $8.61 |
| Average True Range (ATR) | 0.08 | 0.74 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 20.00 | 65.14 |
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.